Following Chinese adults with overweight or obesity to track related health conditions
Follows adults in China with overweight or obesity for 3 years.
Plain-language title generated from the registry record
Registry title: Chinese Overweight/Obesity Cohort: Metabolic & Comorbidity Risks
Key facts
- Where
- Taiyuan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults in China who are overweight or obese. They are followed for 3 years to see which health problems develop.
- Age
- 18 to 79 years
- Sex
- All sexes can join.
- Disease stage
- Overweight or obesity, with a BMI of 23.0 kg/m² or higher. People are grouped as overweight, mild, moderate or severe obesity.
- Biomarker or test result
- Must be willing to give fasting blood samples for storage.
Main reasons for not taking part
- Obesity caused by another illness, such as Cushing's syndrome, hypothyroidism, drugs or genes
- End-stage severe chronic disease, such as refractory heart failure, advanced malignancy or AIDS
- Severe psychiatric disorder or cognitive impairment
- Pregnancy or breastfeeding
- Taking part in another weight-loss or metabolic intervention trial
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Source: NCT07884903, who can take part
Where in China
- Department of Endocrinology, Shanxi Bethune HospitalTaiyuan, ChinaContact: Junwei Wang, DoctorNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanxi Bethune Hospital
- Trial code
- NCT07884903
- Record updated
- 21 October 2026
- Original description
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects the development of obesity-related diseases over a 3-year period.Read full original descriptionShow less
A National Multicenter Prospective Cohort Study on the Incidence Characteristics and Risk Associations of Metabolic and Multi-system Comorbidities in Overweight and Obese Populations Stratified by Body Mass Index
This is a nationwide, multi-center, long-term follow-up study of overweight and obese adults in China. The study aims to recruit approximately 26,000 participants across 39 hospitals to better understand how body weight affects the development of obesity-related diseases over a 3-year period.
Eligible participants are adults aged 18 to 79 years with a body mass index (BMI) of 23 kg/m² or higher. Participants will be grouped into four categories based on their BMI: overweight, mild obesity, moderate obesity, and severe obesity.
At the beginning of the study, all participants will undergo a comprehensive health assessment, including physical measurements, body composition analysis, blood tests, and lifestyle questionnaires. Participants will then be followed for 3 years with annual check-ins to track any new health conditions.
The main goal is to identify the 3-year risk of developing conditions such as type 2 diabetes, fatty liver disease, high blood pressure, and heart disease in different weight groups. This information will help doctors better predict and prevent obesity-related health problems in the future.
Participation is voluntary, and all personal information will be kept confidential.
Inclusion: Adults aged 18 to 79 years; BMI ≥23.0 kg/m² (overweight or obese per 2026 ADA criteria); Able to provide written informed consent; Capable of completing baseline assessment and 3-year follow-up; Local residency for ≥3 years; Willing to provide fasting blood samples for storage.
Exclusion: Concurrent participation in other weight-loss or metabolic intervention trials; Secondary obesity (Cushing's syndrome, hypothyroidism, drug-induced or genetic obesity); End-stage severe chronic diseases (refractory heart failure, advanced malignancy, AIDS); Severe psychiatric disorders or cognitive impairment; Pregnancy or lactation.